PatentJun 9, 2026, 10:21 AM
NeuroSense Therapeutics Receives Japanese Patent for PrimeC ALS Drug
AI Summary
NeuroSense Therapeutics Ltd. announced that the Japan Patent Office has issued Patent 7857044 for PrimeC, its lead drug candidate for amyotrophic lateral sclerosis (ALS). This patent, which includes 17 claims, provides protection through 2042 for PrimeC's unique formulation and manufacturing process. The company stated that this grant strengthens its global intellectual property portfolio, following recent patents in the U.S., Australia, and Brazil, and supports its long-term commercialization strategy in Japan as it prepares for a pivotal Phase 3 clinical trial.
Key Highlights
- NeuroSense Therapeutics received Japanese Patent 7857044 for PrimeC, its lead drug candidate for ALS.
- The patent includes 17 claims and provides protection through 2042.
- This grant strengthens the company's global intellectual property estate for PrimeC.
- The patent covers the unique formulation and manufacturing process of PrimeC, including its synchronized delivery profile.
- Japan is identified as a key pharmaceutical market, supporting long-term commercialization strategy.
- This follows recent patent grants in the U.S., Australia, and Brazil.
- NeuroSense is preparing for a pivotal Phase 3 clinical trial (PARAGON) for PrimeC after FDA clearance.
Price Impact
More from NRSN